{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T17:08:38Z","timestamp":1771607318019,"version":"3.50.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":92,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Zunyi Municipal Science and Technology Program","award":["Zunshi Kehe HZ [2024] 189"],"award-info":[{"award-number":["Zunshi Kehe HZ [2024] 189"]}]},{"name":"the Science and Technology Fund Project of Guizhou Provincial Health Commission of China","award":["gzwkj2025-063"],"award-info":[{"award-number":["gzwkj2025-063"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03977-z","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T14:54:14Z","timestamp":1763650454000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Research progress on the role of AGC kinase family in bladder cancer"],"prefix":"10.1007","volume":"17","author":[{"given":"Peng","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiulan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"3977_CR1","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.semcancer.2017.04.012","volume":"48","author":"N Isakov","year":"2018","unstructured":"Isakov N. Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression. Semin Cancer Biol. 2018;48:36\u201352. https:\/\/doi.org\/10.1016\/j.semcancer.2017.04.012.","journal-title":"Semin Cancer Biol"},{"key":"3977_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.molimm.2024.06.001","volume":"172","author":"Y Yin","year":"2024","unstructured":"Yin Y, Liu Z, Li Q, Gou M, Han Y, Xu Y. Identification and evolution of PDK-1-like involving lamprey innate immunity. Mol Immunol. 2024;172:47\u201355. https:\/\/doi.org\/10.1016\/j.molimm.2024.06.001.","journal-title":"Mol Immunol"},{"key":"3977_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-019-0112-z","volume":"5","author":"J Fan","year":"2019","unstructured":"Fan J, Gao Y, Lu Y, et al. PKAc-directed interaction and phosphorylation of Ptc is required for hh signaling inhibition in drosophila. Cell Discov. 2019;5:44. https:\/\/doi.org\/10.1038\/s41421-019-0112-z.","journal-title":"Cell Discov"},{"issue":"1","key":"3977_CR4","doi-asserted-by":"publisher","first-page":"e4721","DOI":"10.1016\/j.urolonc.2013.06.017","volume":"32","author":"Y Ou","year":"2014","unstructured":"Ou Y, Zheng X, Gao Y, Shu M, Leng T, Li Y, Yin W, Zhu W, Huang Y, Zhou Y, Tang J, Qiu P, Yan G, Hu J, Ruan H, Hu H. Activation of Cyclic AMP\/PKA pathway inhibits bladder cancer cell invasion by targeting MAP4-dependent microtubule dynamics. Urol Oncol. 2014;32(1):e4721\u20138. https:\/\/doi.org\/10.1016\/j.urolonc.2013.06.017.","journal-title":"Urol Oncol"},{"key":"3977_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbior.2020.100769","volume":"80","author":"AR Black","year":"2021","unstructured":"Black AR, Black JD. The complexities of PKC\u03b1 signaling in cancer. Adv Biol Regul. 2021;80:100769. https:\/\/doi.org\/10.1016\/j.jbior.2020.100769.","journal-title":"Adv Biol Regul"},{"key":"3977_CR6","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1080\/19336918.2018.1546513","volume":"13","author":"SMA Islam","year":"2019","unstructured":"Islam SMA, Patel R, Bommareddy RR, Khalid KM, Acevedo-Duncan M. The modulation of actin dynamics via atypical protein kinase-C activated cofilin regulates metastasis of colorectal cancer cells. Cell Adhes Migr. 2019;13:106\u201320.","journal-title":"Cell Adhes Migr"},{"key":"3977_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-93","volume":"14","author":"J Liu","year":"2014","unstructured":"Liu J, Kong C, Gong D, et al. PKC \u03b1 regulates netrin-1\/UNC5B-mediated survival pathway in bladder cancer. BMC Cancer. 2014;14:93.","journal-title":"BMC Cancer"},{"issue":"3","key":"3977_CR8","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1111\/jcmm.16284","volume":"25","author":"X Zhang","year":"2021","unstructured":"Zhang X, Zhang J, Zhang H, Liu Y, Yin L, Liu X, et al. Exploring the five different genes associated with PKC\u03b1 in bladder cancer based on gene expression microarray. J Cell Mol Med. 2021;25(3):1759\u201370. https:\/\/doi.org\/10.1111\/jcmm.16284.","journal-title":"J Cell Mol Med"},{"key":"3977_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.798319","volume":"9","author":"A Abdelatty","year":"2022","unstructured":"Abdelatty A, Sun Q, Hu J, Wu F, Wei G, Xu H, et al. Pan-cancer study on protein kinase C family as a potential biomarker for the tumors immune landscape and the response to immunotherapy. Front Cell Dev Biol. 2022;9:798319. https:\/\/doi.org\/10.3389\/fcell.2021.798319.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"3977_CR10","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s12885-017-3401-7","volume":"17","author":"J Zheng","year":"2017","unstructured":"Zheng J, Kong C, Yang X, Cui X, Lin X, Zhang Z. Protein kinase C-\u03b1 (PKC\u03b1) modulates cell apoptosis by stimulating nuclear translocation of NF-kappa-B p65 in urothelial cell carcinoma of the bladder. BMC Cancer. 2017;17(1):432. https:\/\/doi.org\/10.1186\/s12885-017-3401-7.","journal-title":"BMC Cancer"},{"issue":"17","key":"3977_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22179276","volume":"22","author":"T Kawano","year":"2021","unstructured":"Kawano T, Tachibana Y, Inokuchi J, Kang JH, Murata M, Eto M. Identification of activated protein kinase C\u03b1 (PKC\u03b1) in the urine of orthotopic bladder cancer xenograft model as a potential biomarker for the diagnosis of bladder cancer. Int J Mol Sci. 2021;22(17):9276. https:\/\/doi.org\/10.3390\/ijms22179276.","journal-title":"Int J Mol Sci"},{"key":"3977_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1442555","volume":"15","author":"L Jin","year":"2024","unstructured":"Jin L, Chen T, Sun H, Dai G, Yao Q, Yuan F, et al. The clinical significance and anti-tumor role of PRKG1 in bladder cancer. Front Immunol. 2024;15:1442555. https:\/\/doi.org\/10.3389\/fimmu.2024.1442555.","journal-title":"Front Immunol"},{"issue":"13","key":"3977_CR13","doi-asserted-by":"publisher","first-page":"5355","DOI":"10.1158\/0008-5472.CAN-07-6869","volume":"68","author":"B Cen","year":"2008","unstructured":"Cen B, Deguchi A, Weinstein IB. Activation of protein kinase G increases the expression of p21CIP1, p27KIP1, and histidine triad protein 1 through Sp1. Cancer Res. 2008;68(13):5355\u201362. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-6869.","journal-title":"Cancer Res"},{"issue":"1","key":"3977_CR14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jid.2021.06.011","volume":"142","author":"M Quadri","year":"2022","unstructured":"Quadri M, Comitato A, Palazzo E, Tiso N, Rentsch A, Pellacani G, et al. Activation of cGMP-dependent protein kinase restricts melanoma growth and invasion by interfering with the EGF\/EGFR pathway. J Invest Dermatol. 2022;142(1):201\u201311. https:\/\/doi.org\/10.1016\/j.jid.2021.06.011.","journal-title":"J Invest Dermatol"},{"issue":"10","key":"3977_CR15","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1517\/13543784.10.10.1875","volume":"10","author":"ET Goluboff","year":"2001","unstructured":"Goluboff ET. Exisulind, a selective apoptotic antineoplastic drug. Expert Opin Investig Drugs. 2001;10(10):1875\u201382. https:\/\/doi.org\/10.1517\/13543784.10.10.1875.","journal-title":"Expert Opin Investig Drugs"},{"issue":"24","key":"3977_CR16","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.7150\/jca.25811","volume":"9","author":"JB Chen","year":"2018","unstructured":"Chen JB, Zhang M, Zhang XL, Cui Y, Liu PH, Hu J, et al. Glucocorticoid-inducible kinase 2 promotes bladder cancer cell proliferation, migration and invasion by enhancing \u03b2-catenin\/c-Myc signaling pathway. J Cancer. 2018;9(24):4774\u201382. https:\/\/doi.org\/10.7150\/jca.25811.","journal-title":"J Cancer"},{"issue":"3","key":"3977_CR17","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1080\/15384047.2018.1529098","volume":"20","author":"E Sun","year":"2018","unstructured":"Sun E, Liu K, Zhao K, Wang L. Serine\/threonine kinase 32 C is overexpressed in bladder cancer and contributes to tumor progression. Cancer Biol Ther. 2018;20(3):307\u201320.","journal-title":"Cancer Biol Ther"},{"issue":"9","key":"3977_CR18","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1158\/1535-7163.MCT-18-0063","volume":"17","author":"BL Woolbright","year":"2018","unstructured":"Woolbright BL, Choudhary D, Mikhalyuk A, Trammel C, Shanmugam S, Abbott E, et al. The role of pyruvate dehydrogenase kinase-4 (PDK4) in bladder cancer and chemoresistance. Mol Cancer Ther. 2018;17(9):2004\u201312. https:\/\/doi.org\/10.1158\/1535-7163.MCT-18-0063.","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"3977_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061654","volume":"15","author":"BL Woolbright","year":"2023","unstructured":"Woolbright BL, Rajendran G, Abbott E, Martin A, Didde R, Dennis K, et al. Pyruvate dehydrogenase kinase 4 deficiency increases tumorigenesis in a murine model of bladder cancer. Cancers (Basel). 2023;15(6):1654. https:\/\/doi.org\/10.3390\/cancers15061654.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"3977_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04963-x","volume":"13","author":"K Chen","year":"2022","unstructured":"Chen K, Li Y, Zhang X, Ullah R, Tong J, Shen Y. The role of the PI3K\/AKT signalling pathway in the corneal epithelium: recent updates. Cell Death Dis. 2022;13(5):513. https:\/\/doi.org\/10.1038\/s41419-022-04963-x.","journal-title":"Cell Death Dis"},{"issue":"6","key":"3977_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065679","volume":"8","author":"DX Zhuo","year":"2013","unstructured":"Zhuo DX, Zhang XW, Jin B, Zhang Z, Xie BS, Wu CL, et al. CSTP1, a novel protein phosphatase, blocks cell cycle, promotes cell apoptosis, and suppresses tumor growth of bladder cancer by directly dephosphorylating Akt at Ser473 site. PLoS ONE. 2013;8(6):e65679. https:\/\/doi.org\/10.1371\/journal.pone.0065679.","journal-title":"PLoS ONE"},{"key":"3977_CR22","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/978-1-4939-7234-0_23","volume":"1655","author":"A Sathe","year":"2018","unstructured":"Sathe A, Nawroth R. Targeting the PI3K\/AKT\/mTOR pathway in bladder cancer. Methods Mol Biol. 2018;1655:335\u201350. https:\/\/doi.org\/10.1007\/978-1-4939-7234-0_23.","journal-title":"Methods Mol Biol"},{"issue":"12","key":"3977_CR23","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1007\/s11010-022-04454-9","volume":"477","author":"MC Chen","year":"2022","unstructured":"Chen MC, Annseles Rajula S, Bharath Kumar V, Hsu CH, Day CH, Chen RJ, et al. Tannic acid attenuate AKT phosphorylation to inhibit UMUC3 bladder cancer cell proliferation. Mol Cell Biochem. 2022;477(12):2863\u20139. https:\/\/doi.org\/10.1007\/s11010-022-04454-9.","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"3977_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.31501","volume":"240","author":"L Guo","year":"2024","unstructured":"Guo L, Zhao Y, Bai X, Wang X, Tuoheti K, Cao Y, et al. RRM2 is a putative biomarker and promotes bladder cancer progression via PI3K\/AKT\/mTOR pathway. J Cell Physiol. 2024;(1):e31501. https:\/\/doi.org\/10.1002\/jcp.31501.","journal-title":"J Cell Physiol"},{"issue":"4","key":"3977_CR25","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.7150\/ijbs.83774","volume":"20","author":"W Du","year":"2024","unstructured":"Du W, Tu S, Zhang W, Zhang Y, Liu W, Xiong K, et al. UPP1 enhances bladder cancer progression and gemcitabine resistance through AKT. Int J Biol Sci. 2024;20(4):1389\u2013409. https:\/\/doi.org\/10.7150\/ijbs.83774.","journal-title":"Int J Biol Sci"},{"key":"3977_CR26","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ctrv.2016.03.005","volume":"45","author":"F Massari","year":"2016","unstructured":"Massari F, Ciccarese C, Santoni M, Iacovelli R, Mazzucchelli R, Piva F, et al. Metabolic phenotype of bladder cancer. Cancer Treat Rev. 2016;45:46\u201357. https:\/\/doi.org\/10.1016\/j.ctrv.2016.03.005.","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"3977_CR27","doi-asserted-by":"publisher","first-page":"816","DOI":"10.7150\/jca.17759","volume":"8","author":"Y Li","year":"2017","unstructured":"Li Y, Guo G, Song J, Cai Z, Yang J, Chen Z, et al. B7-H3 promotes the migration and invasion of human bladder cancer cells via the PI3K\/Akt\/STAT3 signaling pathway. J Cancer. 2017;8(5):816\u201324. https:\/\/doi.org\/10.7150\/jca.17759.","journal-title":"J Cancer"},{"issue":"5","key":"3977_CR28","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2020.9238","volume":"20","author":"Q Du","year":"2020","unstructured":"Du Q, Chen J. SNHG1 promotes proliferation, migration and invasion of bladder cancer cells via the PI3K\/AKT signaling pathway. Exp Ther Med. 2020;20(5):110. https:\/\/doi.org\/10.3892\/etm.2020.9238.","journal-title":"Exp Ther Med"},{"issue":"1","key":"3977_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-46091-2","volume":"13","author":"A Janev","year":"2023","unstructured":"Janev A, Ramuta T\u017d, Jerman UD, Obradovi\u0107 H, Kamen\u0161ek U, \u010cema\u017ear M, et al. Human amniotic membrane inhibits migration and invasion of muscle-invasive bladder cancer urothelial cells by downregulating the FAK\/PI3K\/Akt\/mTOR signalling pathway. Sci Rep. 2023;13(1):19227. https:\/\/doi.org\/10.1038\/s41598-023-46091-2.","journal-title":"Sci Rep"},{"issue":"12","key":"3977_CR30","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202301095R","volume":"37","author":"H Chen","year":"2023","unstructured":"Chen H, Ma L, Yang W, Li Y, Ji Z. POLR3G promotes EMT via PI3K\/AKT signaling pathway in bladder cancer. FASEB J. 2023;37(12):e23260. https:\/\/doi.org\/10.1096\/fj.202301095R.","journal-title":"FASEB J"},{"issue":"8","key":"3977_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/md15080238","volume":"15","author":"TC Cheng","year":"2017","unstructured":"Cheng TC, Din ZH, Su JH, Wu YJ, Liu CI. Sinulariolide suppresses cell migration and invasion by inhibiting matrix metalloproteinase-2\/-9 and urokinase through the PI3K\/AKT\/mTOR signaling pathway in human bladder cancer cells. Mar Drugs. 2017;15(8):238. https:\/\/doi.org\/10.3390\/md15080238.","journal-title":"Mar Drugs"},{"issue":"7","key":"3977_CR32","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1111\/cas.14078","volume":"110","author":"S Qiu","year":"2019","unstructured":"Qiu S, Deng L, Liao X, Nie L, Qi F, Jin K, et al. Tumor-associated macrophages promote bladder tumor growth through PI3K\/AKT signal induced by collagen. Cancer Sci. 2019;110(7):2110\u20138. https:\/\/doi.org\/10.1111\/cas.14078.","journal-title":"Cancer Sci"},{"issue":"1","key":"3977_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-00902-8","volume":"15","author":"L Tang","year":"2024","unstructured":"Tang L, Xu H, Wu T, Wu W, Lu Y, Gu J, et al. Advances in tumor microenvironment and underlying molecular mechanisms of bladder cancer: a systematic review. Discover Oncol. 2024;15(1):111. https:\/\/doi.org\/10.1007\/s12672-024-00902-8.","journal-title":"Discover Oncol"},{"issue":"1","key":"3977_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22(1):138. https:\/\/doi.org\/10.1186\/s12943-023-01827-6.","journal-title":"Mol Cancer"},{"key":"3977_CR35","doi-asserted-by":"publisher","first-page":"12205","DOI":"10.2147\/CMAR.S273442","volume":"12","author":"D Qiu","year":"2020","unstructured":"Qiu D, Zhu Y, Cong Z. YAP triggers bladder cancer proliferation by affecting the MAPK pathway. Cancer Manag Res. 2020;12:12205\u201314. https:\/\/doi.org\/10.2147\/CMAR.S273442.","journal-title":"Cancer Manag Res"},{"key":"3977_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01705-z","volume":"8","author":"ME Bahar","year":"2023","unstructured":"Bahar ME, Kim HJ, Kim DR. Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies. Sig Transduct Target Ther. 2023;8:455. https:\/\/doi.org\/10.1038\/s41392-023-01705-z.","journal-title":"Sig Transduct Target Ther"},{"issue":"10","key":"3977_CR37","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1002\/2211-5463.12964","volume":"10","author":"T Jiang","year":"2020","unstructured":"Jiang T, Lu X, Yang F, Wang M, Yang H, Xing N. LMTK3 promotes tumorigenesis in bladder cancer via the ERK\/MAPK pathway. FEBS Open Bio. 2020;10(10):2107\u201321. https:\/\/doi.org\/10.1002\/2211-5463.12964.","journal-title":"FEBS Open Bio"},{"issue":"21","key":"3977_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232113508","volume":"23","author":"F Song","year":"2022","unstructured":"Song F, Kotolloshi R, Gajda M, H\u00f6lzer M, Grimm MO, Steinbach D. Reduced IQGAP2 promotes bladder cancer through regulation of MAPK\/ERK pathway and cytokines. Int J Mol Sci. 2022;23(21):13508. https:\/\/doi.org\/10.3390\/ijms232113508.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3977_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-61302-0","volume":"14","author":"G Cheng","year":"2024","unstructured":"Cheng G, Zhou Z, Li S, Yang S, Wang Y, Ye Z, et al. Predicting bladder cancer survival with high accuracy: insights from MAPK pathway-related genes. Sci Rep. 2024;14(1):10482. https:\/\/doi.org\/10.1038\/s41598-024-61302-0.","journal-title":"Sci Rep"},{"key":"3977_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2023.110893","volume":"112","author":"F Zou","year":"2023","unstructured":"Zou F, Rao T, Chen W, Song T, Li T, Hu W, et al. DUSP2 affects bladder cancer prognosis by down-regulating MEK\/ERK and P38 MAPK signaling pathways through PTPN7. Cell Signal. 2023;112:110893. https:\/\/doi.org\/10.1016\/j.cellsig.2023.110893.","journal-title":"Cell Signal"},{"key":"3977_CR41","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1200\/JCO.2024.42.4_suppl.672","volume":"42","author":"DA Vincent","year":"2024","unstructured":"Vincent DA, et al. MAPK pathway alterations as a targetable vulnerability in bladder cancer. JCO. 2024;42:672\u2013672. https:\/\/doi.org\/10.1200\/JCO.2024.42.4_suppl.672.","journal-title":"JCO"},{"issue":"1","key":"3977_CR42","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1158\/1078-0432.CCR-18-0685","volume":"25","author":"C Rubio","year":"2019","unstructured":"Rubio C, Mart\u00ednez-Fern\u00e1ndez M, Segovia C, Lodewijk I, Suarez-Cabrera C, Segrelles C, et al. CDK4\/6 inhibitor as a novel therapeutic approach for advanced bladder cancer independently of RB1 status. Clin Cancer Res. 2019;25(1):390\u2013402. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0685.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3977_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45796-w","volume":"15","author":"J Ma","year":"2024","unstructured":"Ma J, Li L, Ma B, Liu T, Wang Z, Ye Q, et al. MYC induces CDK4\/6 inhibitors resistance by promoting pRB1 degradation. Nat Commun. 2024;15(1):1871. https:\/\/doi.org\/10.1038\/s41467-024-45796-w.","journal-title":"Nat Commun"},{"issue":"1","key":"3977_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-024-00529-y","volume":"13","author":"W Peng","year":"2024","unstructured":"Peng W, Zhang H, Yin M, Kong D, Kang L, Teng X, et al. Combined inhibition of PI3K and STAT3 signaling effectively inhibits bladder cancer growth. Oncogenesis. 2024;13(1):29. https:\/\/doi.org\/10.1038\/s41389-024-00529-y.","journal-title":"Oncogenesis"},{"issue":"6","key":"3977_CR45","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.3892\/ijo.2020.5021","volume":"56","author":"R Patel","year":"2020","unstructured":"Patel R, Islam SA, Bommareddy RR, Smalley T, Acevedo-Duncan M. Simultaneous Inhibition of atypical protein kinase\u2013C and mTOR impedes bladder cancer cell progression. Int J Oncol. 2020;56(6):1373\u201386. https:\/\/doi.org\/10.3892\/ijo.2020.5021.","journal-title":"Int J Oncol"},{"issue":"5","key":"3977_CR46","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2024.5691","volume":"65","author":"Y Jin","year":"2024","unstructured":"Jin Y, Wang C, Feng K, Wang X, Tong M, Tong G. Emodin inhibits benzidine-enhanced survival and migration of upper urinary tract urothelial carcinoma cells by targeting the PKA\/COX2 signaling pathway. Int J Oncol. 2024;65(5):103. https:\/\/doi.org\/10.3892\/ijo.2024.5691.","journal-title":"Int J Oncol"},{"key":"3977_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.154947","volume":"119","author":"FT Hsu","year":"2023","unstructured":"Hsu FT, Liu WL, Lee SR, Jeng LB, Chen JH. Unveiling nature\u2019s potential weapon: magnolol\u2019s role in combating bladder cancer by upregulating the miR-124 and inactivating PKC-\u03b4\/ERK axis. Phytomedicine. 2023;119:154947. https:\/\/doi.org\/10.1016\/j.phymed.2023.154947.","journal-title":"Phytomedicine"},{"issue":"1","key":"3977_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17512433.2020.1702025","volume":"13","author":"K Montazeri","year":"2020","unstructured":"Montazeri K, Bellmunt J. Erdafitinib for the treatment of metastatic bladder cancer. Expert Rev Clin Pharmacol. 2020;13(1):1\u20136. https:\/\/doi.org\/10.1080\/17512433.2020.1702025.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"3977_CR49","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.radonc.2006.07.032","volume":"80","author":"SR Vink","year":"2006","unstructured":"Vink SR, Schellens JH, Beijnen JH, Sindermann H, Engel J, Dubbelman R, et al. Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours. Radiother Oncol. 2006;80(2):207\u201313. https:\/\/doi.org\/10.1016\/j.radonc.2006.07.032.","journal-title":"Radiother Oncol"},{"issue":"4","key":"3977_CR50","doi-asserted-by":"publisher","first-page":"395","DOI":"10.18632\/oncoscience.147","volume":"2","author":"C Amantini","year":"2015","unstructured":"Amantini C, Morelli MB, Santoni M, Soriani A, Cardinali C, Farfariello V, et al. Sorafenib induces cathepsin B-mediated apoptosis of bladder cancer cells by regulating the Akt\/PTEN pathway. The Akt inhibitor, perifosine, enhances the sorafenib-induced cytotoxicity against bladder cancer cells. Oncoscience. 2015;2(4):395\u2013409. https:\/\/doi.org\/10.18632\/oncoscience.147.","journal-title":"Oncoscience"},{"key":"3977_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.539527","volume":"10","author":"M Peng","year":"2021","unstructured":"Peng M, Xiao D, Bu Y, Long J, Yang X, Lv S, et al. Novel combination therapies for the treatment of bladder cancer. Front Oncol. 2021;10:539527. https:\/\/doi.org\/10.3389\/fonc.2020.539527.","journal-title":"Front Oncol"},{"issue":"10","key":"3977_CR52","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1038\/labinvest.2010.133","volume":"90","author":"CB Ching","year":"2010","unstructured":"Ching CB, Hansel DE. Expanding therapeutic targets in bladder cancer: the PI3K\/Akt\/mTOR pathway. Lab Invest. 2010;90(10):1406\u201314. https:\/\/doi.org\/10.1038\/labinvest.2010.133.","journal-title":"Lab Invest"},{"issue":"2","key":"3977_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020747","volume":"22","author":"J Torres-Jim\u00e9nez","year":"2021","unstructured":"Torres-Jim\u00e9nez J, Albarr\u00e1n-Fern\u00e1ndez V, Pozas J, Rom\u00e1n-Gil MS, Esteban-Villarrubia J, Carrato A, et al. Novel tyrosine kinase targets in urothelial carcinoma. Int J Mol Sci. 2021;22(2):747. https:\/\/doi.org\/10.3390\/ijms22020747.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"3977_CR54","doi-asserted-by":"publisher","first-page":"4378","DOI":"10.1016\/j.apsb.2024.08.003","volume":"14","author":"J Yu","year":"2024","unstructured":"Yu J, Xiang Y, Gao Y, Chang S, Kong R, Lv X, et al. PKC\u03b1 inhibitors promote breast cancer immune evasion by maintaining PD-L1 stability. Acta Pharm Sin B. 2024;14(10):4378\u201395. https:\/\/doi.org\/10.1016\/j.apsb.2024.08.003.","journal-title":"Acta Pharm Sin B"},{"key":"3977_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-018-0265-8","volume":"9","author":"ME Picco","year":"2019","unstructured":"Picco ME, Castro MV, Quezada MJ, Barbero G, Villanueva MB, Fern\u00e1ndez NB, et al. STAT3 enhances the constitutive activity of AGC kinases in melanoma by transactivating PDK1. Cell Biosci. 2019;9:3. https:\/\/doi.org\/10.1186\/s13578-018-0265-8.","journal-title":"Cell Biosci"},{"key":"3977_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215593","volume":"535","author":"M Artemenko","year":"2022","unstructured":"Artemenko M, Zhong SSW, To SKY, Wong AST. P70 S6 kinase as a therapeutic target in cancers: more than just an mTOR effector. Cancer Lett. 2022;535:215593. https:\/\/doi.org\/10.1016\/j.canlet.2022.215593.","journal-title":"Cancer Lett"},{"key":"3977_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He Y, Sun MM, Zhang GG, et al. Targeting PI3K\/Akt signal transduction for cancer therapy. Sig Transduct Target Ther. 2021;6:425. https:\/\/doi.org\/10.1038\/s41392-021-00828-5.","journal-title":"Sig Transduct Target Ther"},{"issue":"7","key":"3977_CR58","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv171","volume":"107","author":"G Xue","year":"2015","unstructured":"Xue G, Zippelius A, Wicki A, Mandal\u00e0 M, Tang F, Massi D, et al. Integrated Akt\/PKB signaling in immunomodulation and its potential role in cancer immunotherapy. J Natl Cancer Inst. 2015;107(7):djv171. https:\/\/doi.org\/10.1093\/jnci\/djv171.","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"3977_CR59","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1158\/1078-0432.CCR-11-3313","volume":"18","author":"TA Yap","year":"2012","unstructured":"Yap TA, Walton MI, Grimshaw KM, Te Poele RH, Eve PD, Valenti MR, et al. AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity. Clin Cancer Res. 2012;18(14):3912\u201323. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-3313.","journal-title":"Clin Cancer Res"},{"key":"3977_CR60","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.semcancer.2017.04.011","volume":"48","author":"V Pr\u00eatre","year":"2018","unstructured":"Pr\u00eatre V, Wicki A. Inhibition of Akt and other AGC kinases: a target for clinical cancer therapy? Semin Cancer Biol. 2018;48:70\u20137. https:\/\/doi.org\/10.1016\/j.semcancer.2017.04.011.","journal-title":"Semin Cancer Biol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03977-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03977-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03977-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T16:16:25Z","timestamp":1771604185000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03977-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3977"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03977-z","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"assertion":[{"value":"10 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"360"}}